187 related articles for article (PubMed ID: 37794033)
1. Intravenous administration of BCG in mice promotes natural killer and T cell-mediated antitumor immunity in the lung.
Moreo E; Jarit-Cabanillas A; Robles-Vera I; Uranga S; Guerrero C; Gómez AB; Mata-Martínez P; Minute L; Araujo-Voces M; Felgueres MJ; Esteso G; Uranga-Murillo I; Arias M; Pardo J; Martín C; Valés-Gómez M; Del Fresno C; Sancho D; Aguiló N
Nat Commun; 2023 Oct; 14(1):6090. PubMed ID: 37794033
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the immunologic mechanism of intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors: distribution and function of immune cells.
Chung JY; Lee ES; Lee WJ; Kim HH; Min KJ; Lee C
J Korean Med Sci; 1993 Apr; 8(2):135-44. PubMed ID: 8397930
[TBL] [Abstract][Full Text] [Related]
3. Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment.
Hori S; Miyake M; Tatsumi Y; Morizawa Y; Nakai Y; Onishi S; Onishi K; Iida K; Gotoh D; Itami Y; Tanaka N; Fujimoto K
Oncol Rep; 2019 Mar; 41(3):1863-1874. PubMed ID: 30628699
[TBL] [Abstract][Full Text] [Related]
4. Mycobacterium cell wall: an alternative to intravesical bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer.
Chin JL; Kadhim SA; Batislam E; Karlik SJ; Garcia BM; Nickel JC; Morales A
J Urol; 1996 Sep; 156(3):1189-93. PubMed ID: 8709344
[TBL] [Abstract][Full Text] [Related]
5. Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy.
Chevalier MF; Schneider AK; Cesson V; Dartiguenave F; Lucca I; Jichlinski P; Nardelli-Haefliger D; Derré L
Eur Urol; 2018 Nov; 74(5):540-544. PubMed ID: 30033046
[TBL] [Abstract][Full Text] [Related]
6. Activation of natural killer cells by Bacillus Calmette-Guérin.
Brandau S; Böhle A
Eur Urol; 2001 May; 39(5):518-24. PubMed ID: 11464031
[TBL] [Abstract][Full Text] [Related]
7. Effect of nitric oxide inhibition in Bacillus Calmette-Guerin bladder cancer treatment.
Langle YV; Balarino NP; Belgorosky D; Cresta Morgado PD; Sandes EO; Marino L; Bilbao ER; Zambrano M; Lodillinsky C; Eiján AM
Nitric Oxide; 2020 May; 98():50-59. PubMed ID: 32147582
[TBL] [Abstract][Full Text] [Related]
8. Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials.
Kates M; Matoso A; Choi W; Baras AS; Daniels MJ; Lombardo K; Brant A; Mikkilineni N; McConkey DJ; Kamat AM; Svatek RS; Porten SP; Meeks JJ; Lerner SP; Dinney CP; Black PC; McKiernan JM; Anderson C; Drake CG; Bivalacqua TJ
Clin Cancer Res; 2020 Feb; 26(4):882-891. PubMed ID: 31712383
[TBL] [Abstract][Full Text] [Related]
9. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.
Vandeveer AJ; Fallon JK; Tighe R; Sabzevari H; Schlom J; Greiner JW
Cancer Immunol Res; 2016 May; 4(5):452-62. PubMed ID: 26921031
[TBL] [Abstract][Full Text] [Related]
10. Additive antitumor effect of arsenic trioxide combined with intravesical bacillus Calmette-Guerin immunotherapy against bladder cancer through blockade of the IER3/Nrf2 pathway.
Mao MH; Huang HB; Zhang XL; Li K; Liu YL; Wang P
Biomed Pharmacother; 2018 Nov; 107():1093-1103. PubMed ID: 30257321
[TBL] [Abstract][Full Text] [Related]
11. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
[TBL] [Abstract][Full Text] [Related]
12. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer.
Ratliff TL; Ritchey JK; Yuan JJ; Andriole GL; Catalona WJ
J Urol; 1993 Sep; 150(3):1018-23. PubMed ID: 8102183
[TBL] [Abstract][Full Text] [Related]
13. Intravesical Ty21a Vaccine Promotes Dendritic Cells and T Cell-Mediated Tumor Regression in the MB49 Bladder Cancer Model.
Domingos-Pereira S; Sathiyanadan K; La Rosa S; Polák L; Chevalier MF; Martel P; Hojeij R; Derré L; Haefliger JA; Jichlinski P; Nardelli-Haefliger D
Cancer Immunol Res; 2019 Apr; 7(4):621-629. PubMed ID: 30696629
[TBL] [Abstract][Full Text] [Related]
14. Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion.
Gomes-Giacoia E; Miyake M; Goodison S; Sriharan A; Zhang G; You L; Egan JO; Rhode PR; Parker AS; Chai KX; Wong HC; Rosser CJ
PLoS One; 2014; 9(6):e96705. PubMed ID: 24896845
[TBL] [Abstract][Full Text] [Related]
15. First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guérin.
Meghani K; Cooley LF; Choy B; Kocherginsky M; Swaminathan S; Munir SS; Svatek RS; Kuzel T; Meeks JJ
Eur Urol; 2022 Dec; 82(6):602-610. PubMed ID: 36008193
[TBL] [Abstract][Full Text] [Related]
16. Intravesical oncolytic virotherapy and immunotherapy for non-muscle-invasive bladder cancer mouse model.
Smelser WW; Wang J; Ogden KM; Chang SS; Kirschner AN
BJU Int; 2023 Sep; 132(3):298-306. PubMed ID: 36961272
[TBL] [Abstract][Full Text] [Related]
17. BCG hydrogel promotes CTSS-mediated antigen processing and presentation, thereby suppressing metastasis and prolonging survival in melanoma.
Kremenovic M; Chan AA; Feng B; Bäriswyl L; Robatel S; Gruber T; Tang L; Lee DJ; Schenk M
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35732347
[TBL] [Abstract][Full Text] [Related]
18. Effects of Mycobacterium bovis Calmette et Guérin (BCG) in oncotherapy: Bladder cancer and beyond.
Mukherjee N; Julián E; Torrelles JB; Svatek RS
Vaccine; 2021 Dec; 39(50):7332-7340. PubMed ID: 34627626
[TBL] [Abstract][Full Text] [Related]
19. Cationized liposomal keto-mycolic acids isolated from Mycobacterium bovis bacillus Calmette-Guérin induce antitumor immunity in a syngeneic murine bladder cancer model.
Yoshino T; Miyazaki J; Kojima T; Kandori S; Shiga M; Kawahara T; Kimura T; Naka T; Kiyohara H; Watanabe M; Yamasaki S; Akaza H; Yano I; Nishiyama H
PLoS One; 2019; 14(1):e0209196. PubMed ID: 30608942
[TBL] [Abstract][Full Text] [Related]
20. Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette--Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity.
Newton MR; Askeland EJ; Andresen ED; Chehval VA; Wang X; Askeland RW; O'Donnell MA; Luo Y
Clin Exp Immunol; 2014 Jul; 177(1):261-8. PubMed ID: 24593764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
